{
  "url": "https://openlegislation.uk/eu-regulation-2018-1480/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2018-1480/annex.json",
  "legislation": "eur/2018/1480",
  "legislation_title": "Commission Regulation (EU) 2018/1480 of 4 October 2018 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures and correcting Commission Regulation (EU) 2017/776 (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2018-1480",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": null,
  "text": "Annex VI to Regulation (EC) No 1272/2008 is amended as follows:\n(1) in Part 1, the heading of point 1.1.1.4 is replaced by the following:\n‘ Chemical name ’;\n(2) in Part 3, Table 3.1 is amended as follows:\n(a) the title of the second column is replaced by the following: ‘Chemical name’;\n(b) the title of the penultimate column is replaced by the following: ‘Specific Conc. Limits, M-factors and ATEs (*)\n(*) ATEs for oral and dermal exposure routes are expressed in mg/kg bw, which stands for milligram per kilogram bodyweight.’;\n(c) the entry corresponding to index number 607-414-00-6 is deleted;\n(d) the entries corresponding to index numbers 006-044-00-7, 015-101-00-5, 016-096-00-2, 017-011-00-1, 025-002-00-9, 603-180-00-4, 604-014-00-3, 604-016-00-4, 604-090-00-8, 605-003-00-6, 606-047-009, 607-096-00-9, 607-103-00-5, 607-113-00-X, 607-373-00-4, 613-167-00-5, 613-205-00-0 and 614-001-00-4 are replaced by the following entries respectively:\nIndex No\nChemical name\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATEs\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘006-044-00-7\nisoproturon (ISO);\n3-(4-isopropylphenyl)-1,1-dimethylurea\n251-835-4\n34123-59-6\nCarc. 2\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH373 (blood)\nH400\nH410\nGHS08\nGHS09\nWng\nH351\nH373 (blood)\nH410\nM = 10\nM = 10’\n‘015-101-00-5\nphosmet (ISO);\nS-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl] O,O-dimethyl phosphorodithioate;\nO,O-dimethyl-S-phthalimidomethyl phosphorodithioate\n211-987-4\n732-11-6\nRepr. 2\nAcute Tox. 4\nAcute Tox. 3\nSTOT SE 1\nAquatic Acute 1\nAquatic Chronic 1\nH361f\nH332\nH301\nH370 (nervous system)\nH400\nH410\nGHS08\nGHS06\nGHS09\nDgr\nH361f\nH332\nH301\nH370 (nervous system)\nH410\nM = 100\nM = 100’\n‘016-096-00-2\nthifensulfuron-methyl (ISO);\nmethyl 3-(4-methoxy-6-methyl-1,3,5-triazin-2-ylcarbamoylsulfamoyl)thiophene-2-carboxylate\n—\n79277-27-3\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 100\nM = 100’\n‘017-011-00-1\nsodium hypochlorite, solution … % Cl active\n231-668-3\n7681-52-9\nSkin Corr. 1B\nEye Dam. 1\nAquatic Acute 1\nAquatic Chronic 1\nH314\nH318\nH400\nH410\nGHS05\nGHS09\nDgr\nH314\nH410\nEUH031\nM = 10\nM = 1\nEUH031:\nC ≥ 5 %\nB’\n‘025-002-00-9\npotassium permanganate\n231-760-3\n7722-64-7\nOx. Sol. 2\nRepr. 2\nAcute Tox. 4 * Aquatic Acute 1 Aquatic Chronic 1\nH272\nH361d\nH302\nH400\nH410\nGHS03\nGHS08\nGHS07\nGHS09\nDgr\nH272\nH361d\nH302\nH410’\n‘603-180-00-4\ncolecalciferol;\ncholecalciferol;\nvitamin D3\n200-673-2\n67-97-0\nAcute Tox. 2 Acute Tox. 2 Acute Tox. 2\nSTOT RE 1\nH330\nH310\nH300\nH372\nGHS06\nGHS08\nDgr\nH330\nH310\nH300\nH372\ninhalation:\nATE = 0,05 mg/L (dusts or mists)\ndermal:\nATE = 50 mg/kg bw\noral:\nATE = 35 mg/kg bw\nSTOT RE 1; H372: C ≥ 3 %\nSTOT RE 2; H373: 0,3 % ≤ C < 3 %’\n‘604-014-00-3\nchlorocresol;\n4-chloro-m-cresol;\n4-chloro-3-methylphenol\n200-431-6\n59-50-7\nAcute Tox. 4\nSkin Corr. 1C\nEye Dam. 1\nSTOT SE 3\nSkin Sens. 1B Aquatic Acute 1\nAquatic Chronic 3\nH302\nH314\nH318\nH335\nH317\nH400\nH412\nGHS07\nGHS05\nGHS09\nDgr\nH302\nH314\nH335\nH317\nH410\nM = 1’\n‘604-016-00-4\n1,2-dihydroxybenzene;\npyrocatechol\n204-427-5\n120-80-9\nCarc. 1Β\nMuta. 2\nAcute Tox. 3\nAcute Tox. 3\nSkin Irrit. 2\nEye Irrit. 2\nH350\nH341\nH311\nH301\nH315\nH319\nGHS08\nGHS06\nDgr\nH350\nH341\nH311\nH301\nH315\nH319\noral:\nATE = 300 mg/kg bw\ndermal:\nATE = 600 mg/kg bw’\n‘604-090-00-8\n4-tert-butylphenol\n202-679-0\n98-54-4\nRepr. 2\nSkin Irrit. 2\nEye Dam. 1\nAquatic Chronic 1\nH361f\nH315\nH318\nH410\nGHS08\nGHS05\nGHS09\nDgr\nH361f\nH315\nH318\nH410\nM = 1’\n‘605-003-00-6\nacetaldehyde;\nethanal\n200-836-8\n75-07-0\nFlam. Liq. 1\nCarc. 1B\nMuta. 2\nSTOT SE 3\nEye Irrit. 2\nH224\nH350\nH341\nH335\nH319\nGHS02\nGHS08\nGHS07\nDgr\nH224\nH350\nH341\nH335\nH319’\n‘606-047-00-9\n2-benzyl-2-dimethylamino-4′-morpholinobutyrophenone\n404-360-3\n119313-12-1\nRepr. 1B\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH400\nH410\nGHS08\nGHS09\nDgr\nH360D\nH410’\n‘607-096-00-9\nmaleic anhydride\n203-571-6\n108-31-6\nAcute Tox. 4\nSTOT RE 1\nSkin Corr. 1B\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1A\nH302\nH372 (respiratory system) (inhalation)\nH314\nH318\nH334\nH317\nGHS07\nGHS08\nGHS05\nDgr\nH302\nH372 (respiratory system) (inhalation)\nH314\nH334\nH317\nEUH071\nSkin Sens. 1A; H317: C ≥ 0,001 %’\n‘607-103-00-5\nsuccinic anhydride\n203-570-0\n108-30-5\nAcute Tox. 4\nSkin Corr. 1\nEye Dam. 1\nResp. Sens. 1\nSkin Sens. 1\nH302\nH314\nH318\nH334\nH317\nGHS07\nGHS05\nGHS08\nDgr\nH302\nH314\nH334\nH317\nEUH071’\n‘607-113-00-X\nisobutyl methacrylate\n202-613-0\n97-86-9\nFlam. Liq. 3\nSTOT SE 3\nSkin Irrit. 2\nSkin Sens. 1B\nH226\nH335\nH315\nH317\nGHS02\nGHS07\nWng\nH226\nH335\nH315\nH317\nD’\n‘607-373-00-4\nquizalofop-P-tefuryl (ISO); (+/–) tetrahydrofurfuryl (R)-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate\n414-200-4\n200509-41-7\nCarc. 2\nRepr. 2\nAcute Tox. 4\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH361fd\nH302\nH373\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH361fd\nH302\nH373\nH410\nM = 1\nM = 1’\n‘613-167-00-5\nreaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one and 2-methyl-2H-isothiazol-3-one (3:1)\n—\n55965-84-9\nAcute Tox. 2\nAcute Tox. 2\nAcute Tox. 3\nSkin Corr. 1C\nEye Dam. 1\nSkin Sens. 1A Aquatic Acute 1\nAquatic Chronic 1\nH330\nH310\nH301\nH314\nH318\nH317\nH400\nH410\nGHS06\nGHS05\nGHS09\nDgr\nH330\nH310\nH301\nH314\nH317\nH410\nEUH071\nSkin Corr. 1C; H314: C ≥ 0,6 %\nSkin Irrit. 2; H315: 0,06 % ≤ C < 0,6 %\nEye Dam. 1; H318: C ≥ 0,6 %\nEye Irrit. 2; H319: 0,06 % ≤ C < 0,6 %\nSkin Sens. 1A; H317: C ≥ 0,0015 %\nM = 100\nM = 100\nB’\n‘613-205-00-0\npropiconazole (ISO); (2RS,4RS;2RS,4SR)-1-{[2-(2,4-dichlorophenyl)-4-propyl-1,3-dioxolan-2-yl]methyl}-1H-1,2,4-triazole\n262-104-4\n60207-90-1\nRepr. 1B\nAcute Tox. 4\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH360D\nH302\nH317\nH400\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH360D\nH302\nH317\nH410\nM = 1\nM = 1’\n‘614-001-00-4\nnicotine (ISO);\n3-[(2S)-1-methylpyrrolidin-2-yl]pyridine\n200-193-3\n54-11-5\nAcute Tox. 2\nAcute Tox. 2\nAcute Tox. 2\nAquatic Chronic 2\nH330\nH310\nH300\nH411\nGHS06\nGHS09\nDgr\nH330\nH310\nH300\nH411\ninhalation:\nATE = 0,19 mg/L (dusts or mists)\ndermal:\nATE = 70 mg/kg bw\noral:\nATE = 5 mg/kg bw’\n(e) the following entries are inserted in the appropriate places, following the order of the entries set out in Table 3.1:\nIndex No\nChemical name\nEC No\nCAS No\nClassification\nLabelling\nSpecific Conc. Limits, M-factors and ATEs\nNotes\nHazard Class and Category Code(s)\nHazard statement Code(s)\nPictogram, Signal Word Code(s)\nHazard statement Code(s)\nSuppl. Hazard statement Code(s)\n‘604-094-00-X\nisoeugenol; [1]\n(E)-2-methoxy-4-(prop-1-enyl)phenol; [2]\n(Z)-2-methoxy-4-(prop-1-enyl)phenol [3]\n202-590-7 [1]\n227-678-2 [2]\n227-633-7 [3]\n97-54-1 [1]\n5932-68-3 [2]\n5912-86-7 [3]\nSkin Sens. 1A\nH317\nGHS07\nWng\nH317\nSkin Sens. 1A; H317: C ≥ 0,01 %’\n‘607-724-00-1\n2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (1R,3R)-2,2-dimethyl-3-[(1Z)-prop-1-en-1-yl]cyclopropanecarboxylate; epsilon-metofluthrin\n—\n240494-71-7\nAcute Tox. 4\nAcute Tox. 3\nSTOT SE 1\nSTOT RE 2\nAquatic Acute 1\nAquatic Chronic 1\nH332\nH301\nH370 (nervous system)\nH373\nH400\nH410\nGHS06\nGHS08\nGHS09\nDgr\nH332\nH301\nH370 (nervous system)\nH373\nH410\nM = 100\nM = 100’\n‘607-725-00-7\nisopropyl (2E,4E,7S)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienoate; S-methoprene\n—\n65733-16-6\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 1\nM = 1’\n‘607-726-00-2\npinoxaden (ISO);\n8-(2,6-diethyl-4-methylphenyl)-7-oxo-1,2,4,5-tetrahydro-7H-pyrazolo[1,2-d][1,4,5]oxadiazepin-9-yl 2,2-dimethylpropanoate\n—\n243973-20-8\nRepr. 2\nAcute Tox. 4\nAcute Tox. 4\nEye Irrit. 2\nSTOT SE 3\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 3\nH361d\nH332\nH302\nH319\nH335\nH317\nH400\nH412\nGHS08\nGHS07\nGHS09\nWng\nH361d\nH332\nH302\nH319\nH335\nH317\nH410\ninhalation:\nATE = 4,63 mg/L (dusts or mists)\noral:\nATE = 500 mg/kg bw\nM = 1’\n‘607-727-00-8\ntetramethrin (ISO);\n(1,3-dioxo-1,3,4,5,6,7-hexahydro-2H-isoindol-2-yl)methyl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropanecarboxylate\n231-711-6\n7696-12-0\nCarc. 2\nAcute Tox. 4\nSTOT SE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH371 (nervous system) (inhalation)\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH371 (nervous system) (inhalation)\nH410\nM = 100\nM = 100’\n‘607-728-00-3\n(1,3,4,5,6,7-hexahydro-1,3-dioxo-2H-isoindol-2-yl)methyl (1R-trans)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate\n214-619-0\n1166-46-7\nCarc. 2\nAcute Tox. 4\nSTOT SE 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH302\nH371 (nervous system) (inhalation)\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH302\nH371 (nervous system) (inhalation)\nH410\nM = 100\nM = 100’\n‘607-729-00-9\nmesosulfuron-methyl (ISO);\nmethyl 2-[(4,6-dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-α-(methanesulfonamido)-p-toluate;\n—\n208465-21-8\nAquatic Acute 1\nAquatic Chronic 1\nH400\nH410\nGHS09\nWng\nH410\nM = 100\nM = 100’\n‘607-730-00-4\nspirodiclofen (ISO);\n3-(2,4-dichlorophenyl)-2-oxo-1-oxaspiro[4.5]dec-3-en-4-yl 2,2-dimethylbutyrate\n—\n148477-71-8\nCarc. 1B\nRepr. 2\nSTOT RE 2\nSkin Sens. 1B\nAquatic Chronic 1\nH350\nH361f\nH373\nH317\nH410\nGHS08\nGHS07\nGHS09\nDgr\nH350\nH361f\nH373\nH317\nH410\nM = 10’\n‘607-731-00-X\nsodium methyl [(4-aminophenyl)sulphonyl]carbamate; sodium methyl (EZ)-sulfanilylcarbonimidate; asulam-sodium\n218-953-8\n2302-17-2\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM = 1\nM = 1’\n‘607-732-00-5\nsalicylic acid\n200-712-3\n69-72-7\nRepr. 2\nAcute Tox. 4\nEye Dam. 1\nH361d\nH302\nH318\nGHS08\nGHS07\nGHS05\nDgr\nH361d\nH302\nH318’\n‘608-068-00-9\nflutianil (ISO);\n(2Z)-{[2-fluoro-5-(trifluoromethyl)phenyl]thio}[3-(2-methoxyphenyl)-1,3-thiazolidin-2-ylidene]acetonitrile\n—\n958647-10-4\nAquatic Chronic 1\nH410\nGHS09\nWng\nH410\nM = 100’\n‘612-293-00-8\nreaction mass of 1-[2-(2-aminobutoxy)ethoxy]but-2-ylamine and 1-({[2-(2-aminobutoxy)ethoxy]methyl}propoxy)but-2-ylamine\n447-920-2\n-\nRepr. 2\nAcute Tox. 4\nSkin Corr. 1B\nEye Dam. 1\nH361f\nH302\nH314\nH318\nGHS08\nGHS07\nGHS05\nDgr\nH361f\nH302\nH314\nEUH071’\n‘613-326-00-9\n2-methylisothiazol-3(2H)-one\n220-239-6\n2682-20-4\nAcute Tox. 2\nAcute Tox. 3\nAcute Tox. 3\nSkin Corr. 1B\nEye Dam. 1\nSkin Sens. 1A\nAquatic Acute 1\nAquatic Chronic 1\nH330\nH311\nH301\nH314\nH318\nH317\nH400\nH410\nGHS05\nGHS06\nGHS09\nDgr\nH330\nH311\nH301\nH314\nH317\nH410\nEUH071\nSkin Sens. 1A; H317: C ≥ 0,0015 %\nM = 10\nM = 1’\n‘613-327-00-4\npyroxsulam (ISO);\nN-(5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-2-methoxy-4-(trifluoromethyl)pyridine-3-sulfonamide\n—\n422556-08-9\nSkin Sens. 1\nAquatic Acute 1\nAquatic Chronic 1\nH317\nH400\nH410\nGHS07\nGHS09\nWng\nH317\nH410\nM = 100\nM = 100’\n‘613-328-00-X\n1-vinylimidazole\n214-012-0\n1072-63-5\nRepr. 1B\nH360D\nGHS08\nDgr\nH360D\nRepr. 1B; H360D: C ≥ 0,03 %’\n‘616-224-00-2\namisulbrom (ISO);\n3-(3-bromo-6-fluoro-2-methylindol-1-ylsulfonyl)-N,N-dimethyl-1H-1,2,4-triazole-1-sulfonamide\n—\n348635-87-0\nCarc. 2\nEye Irrit. 2\nAquatic Acute 1\nAquatic Chronic 1\nH351\nH319\nH400\nH410\nGHS08\nGHS07\nGHS09\nWng\nH351\nH319\nH410\nM = 10\nM = 10’",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2018/1480/annex",
    "retrieved_at": "2026-11-01T14:43:56.165586+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}